Table 2 Active Recruiting Current Clinical Trials with FAK Inhibitors in Various Malignancies
From: Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape
NCI Identifier | Study Description | Tumor Type | Drug Combination with FAK inhibitor* | Phase |
|---|---|---|---|---|
NCT03287271 | ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK | Ovarian | Paclitaxel, Carboplatin VS-6063 (defactinib)* | I/II |
NCT02758587 | Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) | NSCLC, Mesothelioma, Pancreatic Neoplasms | Pembrolizumab Defactinib* | I/II |
NCT02523014 | Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas | Meningioma | Vismodegib GSK2256098* | II |
NCT02546531 | Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer | Advanced solid tumors, Pancreatic Cancer | Gemcitabine, Pembrolizumab Defactinib | I |
NCT02695550 | Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer | NSCLC | CT-707* | I |
NCT03727880 | Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | PDAC | Pembrolizumab Defactinib | II |